Pacific Biosciences of California Stock Price, News & Analysis (NASDAQ:PACB) $8.39 -0.53 (-5.94%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$8.29▼$8.8250-Day Range$5.97▼$9.0352-Week Range$5.74▼$14.55Volume4.27 million shsAverage Volume4.12 million shsMarket Capitalization$2.24 billionP/E RatioN/ADividend YieldN/APrice Target$11.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Pacific Biosciences of California MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside40.6% Upside$11.80 Price TargetShort InterestBearish14.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.25 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.17) to ($1.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector646th out of 948 stocksAnalytical Instruments Industry17th out of 27 stocks 4.4 Analyst's Opinion Consensus RatingPacific Biosciences of California has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.80, Pacific Biosciences of California has a forecasted upside of 40.6% from its current price of $8.39.Amount of Analyst CoveragePacific Biosciences of California has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.67% of the outstanding shares of Pacific Biosciences of California have been sold short.Short Interest Ratio / Days to CoverPacific Biosciences of California has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Pacific Biosciences of California has recently increased by 11.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PACB. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Pacific Biosciences of California this week, compared to 3 articles on an average week.Search Interest15 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows8 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,247,090.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Pacific Biosciences of California is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pacific Biosciences of California are expected to grow in the coming year, from ($1.17) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacific Biosciences of California has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pacific Biosciences of California Stock (NASDAQ:PACB)Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.Read More PACB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PACB Stock News HeadlinesDecember 1, 2023 | finance.yahoo.comWhy Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?November 21, 2023 | seekingalpha.comPacific Biosciences' Revio And Onso Lead Looks Priced In For NowDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 20, 2023 | seekingalpha.comReassessing Pacific Biosciences: Deep Dive Into Q3 2023 Revenue Surge And Market DynamicsNovember 18, 2023 | msn.comUBS Upgrades Pacific Biosciences of California (PACB)November 17, 2023 | seekingalpha.comPacific Biosciences of California rises after UBS upgrades on strong 'Revio' demandNovember 17, 2023 | msn.comPacific Biosciences of California rise after UBS upgrades on strong 'Revio' demandNovember 16, 2023 | msn.comMeet the biotech company Cathie Wood bought half a million shares of this monthDecember 6, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 10, 2023 | finance.yahoo.comCompared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key MetricsNovember 7, 2023 | markets.businessinsider.comAnalyst Expectations for Pacific Biosciences's FutureNovember 6, 2023 | markets.businessinsider.comPositive Outlook and Customer Interest Reinforce Buy Rating for Pacific BiosciencesNovember 2, 2023 | finance.yahoo.comPacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research LeadersNovember 1, 2023 | msn.comCantor Fitzgerald Upgrades Pacific Biosciences of California (PACB)November 1, 2023 | finance.yahoo.comPacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio CompatibleOctober 31, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)October 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Monolithic Power (MPWR), Stem Inc (STEM) and Pacific Biosciences (PACB)October 31, 2023 | finanznachrichten.dePacific Biosciences of California, Inc.: PacBio Announces Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comPacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA ApplicationsOctober 31, 2023 | finance.yahoo.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2023 Earnings Call TranscriptOctober 31, 2023 | finance.yahoo.comPacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue ViewOctober 30, 2023 | markets.businessinsider.comPacific Biosciences of California, Inc. Q3 Loss Decreases, beats estimatesOctober 30, 2023 | finance.yahoo.comPacBio Announces Third Quarter 2023 Financial ResultsOctober 30, 2023 | finance.yahoo.comPacific Biosciences of California Inc (PACB) Reports Q3 2023 Earnings: Revenue Up 72% YoYOctober 29, 2023 | msn.comPacific Biosciences of California Q3 2023 Earnings PreviewOctober 18, 2023 | finance.yahoo.comCathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy?October 17, 2023 | msn.comPiper Sandler Maintains Pacific Biosciences of California (PACB) Neutral RecommendationSee More Headlines Receive PACB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB CUSIP69404D10 CIK1299130 Webwww.pacb.com Phone(650) 521-8000Fax302-636-5454Employees769Year Founded2004Price Target and Rating Average Stock Price Target$11.80 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+40.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-314,250,000.00 Net Margins-182.34% Pretax Margin-188.66% Return on Equity-43.39% Return on Assets-15.58% Debt Debt-to-Equity Ratio1.17 Current Ratio4.80 Quick Ratio4.43 Sales & Book Value Annual Sales$169.52 million Price / Sales13.24 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book3.37Miscellaneous Outstanding Shares267,444,000Free Float263,700,000Market Cap$2.24 billion OptionableOptionable Beta1.78 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Christian O. Henry M.B.A. (Age 55)President, CEO & Director Comp: $1.1MMs. Susan G. Kim (Age 47)Chief Financial Officer Comp: $564.87kMr. Mark Van Oene (Age 50)Chief Operating Officer Comp: $772.11kMr. Jeff Eidel (Age 46)Chief Commercial Officer Comp: $435.62kDr. Stephen Turner (Age 55)Co-Founder & CTO Comp: $341.25kMs. Michele Farmer CPA (Age 43)VP & Chief Accounting Officer Dr. Jonas Korlach Ph.D.Chief Scientific OfficerTrevin RardHead of Investor RelationsDr. Brett Atkins J.D.Ph.D., General Counsel & Corporate SecretaryMs. Natalie WelchChief People OfficerMore ExecutivesKey CompetitorsFluidigmNASDAQ:FLDMHarvard BioscienceNASDAQ:HBIOBerkeley LightsNASDAQ:BLIBionano GenomicsNASDAQ:BNGOAccelerate DiagnosticsNASDAQ:AXDXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 1,941 shares on 11/24/2023Ownership: 0.060%Walleye Trading LLCSold 13,500 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCSold 16,000 shares on 11/21/2023Ownership: 0.000%Comerica BankBought 5,450 shares on 11/21/2023Ownership: 0.002%Tudor Investment Corp Et AlSold 17,400 shares on 11/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PACB Stock Analysis - Frequently Asked Questions Should I buy or sell Pacific Biosciences of California stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PACB shares. View PACB analyst ratings or view top-rated stocks. What is Pacific Biosciences of California's stock price target for 2024? 11 brokers have issued 12-month price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $8.00 to $17.00. On average, they expect the company's stock price to reach $11.80 in the next year. This suggests a possible upside of 40.6% from the stock's current price. View analysts price targets for PACB or view top-rated stocks among Wall Street analysts. How have PACB shares performed in 2023? Pacific Biosciences of California's stock was trading at $8.18 at the start of the year. Since then, PACB shares have increased by 2.6% and is now trading at $8.39. View the best growth stocks for 2023 here. When is Pacific Biosciences of California's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our PACB earnings forecast. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings results on Monday, October, 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. The biotechnology company had revenue of $55.70 million for the quarter, compared to analyst estimates of $48.76 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 43.39% and a negative net margin of 182.34%. The business's quarterly revenue was up 72.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.32) EPS. What ETFs hold Pacific Biosciences of California's stock? ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and BNY Mellon Innovators ETF (BKIV). What is Christian Henry's approval rating as Pacific Biosciences of California's CEO? 2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA). Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.90%), Sumitomo Mitsui Trust Holdings Inc. (5.37%), FMR LLC (1.73%), Bank of New York Mellon Corp (1.76%), Lord Abbett & CO. LLC (1.37%) and Northern Trust Corp (1.05%). Insiders that own company stock include Christian O Henry, Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson. View institutional ownership trends. How do I buy shares of Pacific Biosciences of California? Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Pacific Biosciences of California have any subsidiaries? The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.Read More This page (NASDAQ:PACB) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.